Ann: Prana provides regulatory update for PBT2-PBT.AX, page-67

A fact is that I think there is a Disallowed coming up here. Of course it could be classed as ramping, but if the EU trial is approved I think it is a very good possibility from this cash level. You just keep looking at the past while we have a healthy company here with a Phase3 registration trial planned, with the first drug in a wide platform of neurodegeneration drugs, at just above cash value. I am just a holder and very happy with my investment if/when they get the EU trial underway. If they don't get approval for a trial, we are already close to cash. If they do it unlocks the whole 2000+ drug library and look out.